Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Clinical trial NCT05485961 · RECRUITING

Trial details

NCT number: NCT05485961
Sponsor: CSL Behring
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

End Stage Kidney Disease

Start date: 2022-10-21
Primary completion: 2029-05-22
Enrollment: 3110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.